In critically ill patients, empirical antifungal treatment is commonly used because of poor prognosis of these infections, especially when initial antifungal treatment is inappropriate or delayed. In addition, accuracy of available diagnostic tools is limited. However, excessive use of antifungals is potentially associated with side-effects, higher cost and emergence of pathogenic fungi. We aim to provide a short summary of recent data on invasive fungal infections management to improve antifungal use in critically ill patients.